Reviva Pharmaceuticals Holdings, Inc.
RVPH
$0.68
-$0.01-1.41%
OTC PK
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 7.90M | 8.49M | 8.27M | 7.98M | 8.18M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 16.93M | 20.20M | 22.93M | 27.36M | 29.41M |
| Operating Income | -16.93M | -20.20M | -22.93M | -27.36M | -29.41M |
| Income Before Tax | -16.61M | -19.85M | -22.74M | -27.09M | -28.90M |
| Income Tax Expenses | 17.00K | 18.90K | 20.70K | 17.90K | 17.30K |
| Earnings from Continuing Operations | -16.63 | -19.86 | -22.76 | -27.11 | -28.92 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -16.63M | -19.86M | -22.76M | -27.11M | -28.92M |
| EBIT | -16.93M | -20.20M | -22.93M | -27.36M | -29.41M |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -4.55 | -6.71 | -9.22 | -13.06 | -15.78 |
| Normalized Basic EPS | -2.84 | -4.19 | -5.76 | -8.16 | -9.86 |
| EPS Diluted | -4.55 | -6.71 | -9.22 | -13.06 | -15.78 |
| Normalized Diluted EPS | -2.84 | -4.19 | -5.76 | -8.16 | -9.86 |
| Average Basic Shares Outstanding | 19.09M | 14.53M | 10.63M | 8.68M | 7.72M |
| Average Diluted Shares Outstanding | 19.09M | 14.53M | 10.63M | 8.68M | 7.72M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |